Whanin Pharm (016580) - Total Liabilities

Latest as of June 2026: ₩57.15 Billion KRW ≈ $38.73 Million USD

Based on the latest financial reports, Whanin Pharm (016580) has total liabilities worth ₩57.15 Billion KRW (≈ $38.73 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 016580 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Whanin Pharm - Total Liabilities Trend (2009–2025)

This chart illustrates how Whanin Pharm's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Whanin Pharm's balance sheet.

Whanin Pharm Competitors by Total Liabilities

The table below lists competitors of Whanin Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Aemetis Inc NASDAQ:AMTX	USA	$611.29 Million
West Wits Mining Ltd AU:WWI	Australia	AU$22.12 Million
FACT II Acquisition Corp. Class A Ordinary Shares NASDAQ:FACT	USA	$9.52 Million
Interactive Digital Technologies TWO:6486	Taiwan	NT$1.53 Billion
Joyce Corporation Ltd AU:JYC	Australia	AU$57.55 Million
Rafael Microelectronics TWO:6568	Taiwan	NT$318.71 Million
PKP Cargo S.A. WAR:PKP	Poland	zł5.42 Billion

Liability Composition Analysis (2009–2025)

This chart breaks down Whanin Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Whanin Pharm's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.26	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.13	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.12	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Whanin Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Whanin Pharm (2009–2025)

The table below shows the annual total liabilities of Whanin Pharm from 2009 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩57.88 Billion ≈ $39.23 Million	+18.85%
2024-12-31	₩48.70 Billion ≈ $33.01 Million	+13.22%
2023-12-31	₩43.02 Billion ≈ $29.15 Million	+21.36%
2022-12-31	₩35.45 Billion ≈ $24.02 Million	-1.44%
2021-12-31	₩35.96 Billion ≈ $24.37 Million	+9.12%
2020-12-31	₩32.96 Billion ≈ $22.33 Million	+8.33%
2019-12-31	₩30.42 Billion ≈ $20.62 Million	+8.26%
2018-12-31	₩28.10 Billion ≈ $19.04 Million	-11.50%
2017-12-31	₩31.75 Billion ≈ $21.52 Million	+36.22%
2016-12-31	₩23.31 Billion ≈ $15.80 Million	+23.35%
2012-12-31	₩18.90 Billion ≈ $12.81 Million	+16.26%
2011-12-31	₩16.25 Billion ≈ $11.02 Million	+54.67%
2009-12-31	₩10.51 Billion ≈ $7.12 Million	--

About Whanin Pharm

KO:016580 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$127.64 Million

₩188.35 Billion KRW

Market Cap Rank

#18356 Global

#813 in Korea

Share Price

₩10190.00

Change (1 day)

-0.49%

52-Week Range

₩9230.00 - ₩11930.00

All Time High

₩24391.10